

Drottninggatan 2 Box 1661 SE-111 96 Stockholm Sweden Telephone +46 8-700 17 00 Fax +46 8-10 25 59 www.ratos.se

PRESS RELEASE 22 July 2002

New CEO for Dynal Biotech

Jon Hindar will take up his appointment as CEO of Dynal Biotech on 12 August 2002. He will replace the present CEO, Vigdis Haeggeli, who is leaving the company on 9 August at her own request.

"I see further developing Dynal which operates in a strong, growth industry as an exciting challenge," says Jon Hindar commenting on his new position.

Jon Hindar has a master's degree in chemical engineering. He has broad and thorough industrial and financial experience and his present position is CEO of Fondsfinans, one of the oldest and leading private banking firms in Norway. He previously worked within the Dyno Group as CEO of Dyno Nobel Group in Europe and marketing manager of Dyno Particles. These latter operations are now part of the Dynal Biotech Group.

Dynal Biotech (www.dynalbiotech.com) is the world leader in research, development and production of magnetic and non-magnetic micro particles (beads). The company markets a broad product range based on this technology. Applications for Dynal Biotech's products include separation of biological material. Customers and co-operation partners are found within both industry and research, mainly in the field of diagnostics, genomics and cell therapy. Dynal's main facilities are located in Oslo. The company's products are sold via subsidiaries and distributors in more than 30 countries. In 2001 sales amounted to NOK 483m with a pre-tax profit of NOK 92m. The company has some 240 employees.

Ratos's holding in Dynal Biotech amounts to 25%.

For further information, please contact: Mats Lönnqvist, Senior Investment Manager Ratos, +46 70-591 55 63

Financial calendar 2002:

Six-month report 26 August
Nine-month report 13 November

Ratos is a listed private equity company. The business concept is to maximise shareholder value over time by investing in, developing and divesting primarily unlisted companies. Ratos thus offers stock market players a unique investment opportunity. The net asset value of Ratos's investments is approximately SEK 9 billion. Ratos's holdings include Arcorus, Atle Industri, Camfil, Capona, Dahl, DataVis, DIAB, Dynal Biotech, Gadelius, Haendig, Haglöfs, Hilding Anders, HL Display, Industri Kapital, Intervect, Lindab, Martinsson, Q-Labs, Superfos, Telia Overseas and Yarrow.